guest ::
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
; ; ; ; ; ; ; ; ; ; ; ;
In
Kidney international 108(4,), Seiten/Artikel-Nr.:695-706
2025
Online
DOI: 10.1016/j.kint.2025.05.028
DOI: 10.18154/RWTH-2025-07100
URL: https://publications.rwth-aachen.de/record/1017042/files/1017042.pdf
Einrichtungen
Projekte
Thematische Einordnung (Klassifikation)
DDC: 610
OpenAccess: 
PDF
Dokumenttyp
Journal Article
Format
online, print
Sprache
English
Anmerkung
Peer reviewed article
Externe Identnummern
SCOPUS: SCOPUS:2-s2.0-105013136146
WOS Core Collection: WOS:001620469200013
Interne Identnummern
RWTH-2025-07100
Datensatz-ID: 1017042
Beteiligte Länder
Canada, Germany, USA
; 
; 
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 15 ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
| Typ | Amount | VAT | Currency | Share | Status | Cost centre |
| Other | 100.00 | 7.00 | EUR | 3.74 % | (DEAL) | 021000-932610 |
| Hybrid-OA | 2575.00 | 180.25 | EUR | 96.26 % | (DEAL) | 021000-932610 |
| Sum | 2675.00 | 187.25 | EUR | |||
| Total | 2862.25 |
PDF